Shares surged +6.2% to $57.19 after the FDA approved Moderna's seasonal mRNA flu vaccine for adults 50 and older — the first influenza shot ever built on mRNA technology. The decision is a landmark for the company's platform, but it also kicks off a brutal commercial fight in a market where three incumbents control more than 60% of revenue.
The Approval Unlocks More Than One Product
The approval simultaneously resolves the regulatory blocking condition for two other stalled mRNA vaccine programs , most critically a combined flu-and-COVID shot that Moderna withdrew from FDA review in May 2025 after the agency demanded flu efficacy data the company didn't yet have.
That data now exists in the form of the trial results supporting this approval.
The combo vaccine is already authorized in Europe , and a U.S. resubmission could come soon — a potential two-for-one seasonal shot that would be far more commercially powerful than flu alone.
The Clinical Edge Is Real but Narrow
In a late-stage trial, the vaccine was found to be about 27% more effective than a standard flu shot. That headline number matters, but context does too: accelerated approval in the 65-plus group relied on immune-response comparisons, and Moderna must still run a confirmatory post-marketing trial
over two flu seasons.
Side effects were more frequent than with existing vaccines — a real factor for uptake among seniors already managing multiple health issues.
The Cash Clock Is Still Ticking Moderna is burning money fast. Cash stood at $6.9 billion as of June 30, down from $7.5 billion three months earlier , and the company paid $950 million in July to settle litigation.
R&D spending is projected at roughly $3 billion for 2026.
Management is targeting cash breakeven in 2028 , meaning flu revenue needs to start contributing soon. The global flu vaccine market is valued at roughly $9.5 billion in 2026 , but Sanofi, GSK, and CSL Seqirus collectively hold over 60% of it.
Political Headwinds Add Uncertainty
HHS Secretary Robert F. Kennedy Jr. has repeatedly criticized mRNA technology , and his agency oversaw a regulatory near-death experience for this vaccine earlier this year — a rare refusal-to-file that Moderna ultimately navigated by splitting its application by age group. The approval is a win, but the political environment means CDC vaccination recommendations — which drive pharmacy demand — are no sure thing.
The +6.2% pop prices in the headline. What it doesn't price in: whether Moderna can convert a single approval into durable, recurring seasonal revenue before its cash runway narrows further.